DexCom (NASDAQ:DXCM) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

DexCom (NASDAQ:DXCM - Get Free Report) released its quarterly earnings results on Thursday. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01), Zacks reports. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter in the previous year, the company posted $0.32 EPS. The business's quarterly revenue was up 12.5% on a year-over-year basis. DexCom updated its FY 2025 guidance to EPS.

DexCom Trading Up 16.2 %

NASDAQ DXCM opened at $81.62 on Friday. DexCom has a 52 week low of $57.52 and a 52 week high of $132.26. The company has a 50 day moving average price of $71.46 and a 200 day moving average price of $76.77. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm has a market cap of $32.00 billion, a PE ratio of 57.08, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This trade represents a 8.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares in the company, valued at approximately $10,002,636.06. This trade represents a 4.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,926 shares of company stock worth $4,734,384 over the last three months. Corporate insiders own 0.32% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DexCom stock. Brighton Jones LLC lifted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 257.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,582 shares of the medical device company's stock after acquiring an additional 11,946 shares during the period. Brighton Jones LLC's holdings in DexCom were worth $1,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on DXCM shares. Mizuho initiated coverage on shares of DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. Morgan Stanley increased their price target on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and upped their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Piper Sandler cut their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a report on Friday. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, DexCom currently has an average rating of "Moderate Buy" and a consensus price target of $99.22.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.